Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
- Downstream Processing
BPI Contributor
November 11, 2020
1 Min Read
Sponsored by Cytiva
Future proof your HCP strategy. Four questions to help you decide if your HCP analysis data is ready for next phase approval.
Host cell proteins (HCPs) are a primary source of impurities in biologics development. Scientists must detect and remove HCPs to ensure patient safety and meet regulatory guidelines. If previously undetected HCPs are found in later phases of clinical
trials, scientists will need to redesign the drug substance purification strategy – adding financial and time costs that can create long project delays.
Find out if your HCP analysis data is ready for next phase approval using our online guide. From sample preparation to data analysis, each step affects the next – and ultimately, your results.
About the Author(s)
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More